The Melanoma Research Foundation is committed to advancing a national scientific agenda for melanoma research, coordinating with other leaders and funders, while funding research across the spectrum of melanoma - in prevention, diagnosis and treatment. Components of MRF's strategy include:
- A grant program to stimulate and sustain research in melanoma prevention, diagnosis and treatment. Since 1998, grants have been awarded to young and established investigators, with new outreach to medical students in 2011. In addition, the MRF's CURE OM initiative will fund ocular and uveal melanoma specific research beginning in 2012.
- Proactively partnering with other leaders and funders (NCI, Congress, Department of Defense) to develop and collaborate on a broad agenda for melanoma research that takes full advantage of all opportunities, while sharing challenges.
- Partnering with the Society for Melanoma Research (SMR) to sponsor the annual International Melanoma Congress where early research results are shared and collaboration across disciplines and countries is encouraged.
- Initiating a dialogue with the FDA to explore new regulatory paths for potentially transformational treatments, combination therapies, and co-development of biomarkers to select patients for personalized medicine.
- Launching of a network of leading clinical trial experts and their institutions in 2010, the Melanoma Research Foundation Breakthrough Consortium (MRFBC), to facilitate a coordinated national effort to develop combination therapies.
- An initiative in parallel with the MRFBC to develop a national virtual specimen tracking system across trials and different treatments, utilizing harmonized SOPs, with the goal of facilitating translational research.
Learn more about MRF's role in new melanoma drugs.